Serotonin Signaling and the Hyperpermeable Endothelial Barrier in Sepsis: Clues to a Molecular Mechanism

Overview

Journal J Community Med Public Health

Publisher Gavin Publishers

Date 2024 Feb 19

PMID 38371611

Authors

Fusun Kilic

Affiliations

Soon will be listed here.

Abstract

Sepsis is characterized by a severe systemic inflammatory response caused by hyperpermeability of the endothelial barrier resulting microvascular leakage, which is a leading factor to multiorgan failure. In sepsis, the hyperpermeable endothelial cells contribute to the activation of platelets, which release numerous mediators that affect coagulation, inflammatory response and are believed to directly or indirectly affect the integrity of the endothelial barrier. One such mediator is serotonin (5-hydroxytryptamine, 5-HT), a signaling molecule which mediates a number of cellular functions including regulation of cytoskeletal dynamics associated with barrier function of endothelial cells. The actions of 5-HT are mediated by different types of receptors and terminated via an uptake mechanism of a 5-HT transporter (SERT) on the platelet and endothelial cell. Earlier studies revealed unexpected discoveries concerning the impact of 5-HT signaling on the permeability of the endothelial barrier. These findings have been supported by the clinical reports on the anti-inflammatory property of 5-HT reuptake inhibitor, SSRIs in treating sepsis-related morbidity and mortality. This review focuses on a wide-range of literature to pinpoint cellular and molecular mechanisms that mediate 5-HT-induced microvascular injury in sepsis pathogenesis.

Citing Articles

A Scoping Review of Eosinophilic Pneumonia and Antidepressants: An Association Not to Be Overlooked.

Steiner J, Steuernagel L, Drakopanagiotakis F, Bonelis K, Steiropoulos P Diseases. 2025; 13(1).

PMID: 39851477 PMC: 11764640. DOI: 10.3390/diseases13010013.

References

Podor T, Singh D, Chindemi P, Foulon D, McKelvie R, Weitz J . Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem. 2001; 277(9):7529-39. DOI: 10.1074/jbc.M109675200. View

Shannon O . The role of platelets in sepsis. Res Pract Thromb Haemost. 2021; 5(1):27-37. PMC: 7845078. DOI: 10.1002/rth2.12465. View

Cloutier N, Pare A, Farndale R, Schumacher H, Nigrovic P, Lacroix S . Platelets can enhance vascular permeability. Blood. 2012; 120(6):1334-43. DOI: 10.1182/blood-2012-02-413047. View

Aird W . The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003; 101(10):3765-77. DOI: 10.1182/blood-2002-06-1887. View

Spanos A, Jhanji S, Vivian-Smith A, Harris T, Pearse R . Early microvascular changes in sepsis and severe sepsis. Shock. 2009; 33(4):387-91. DOI: 10.1097/SHK.0b013e3181c6be04. View

Tang D, Bai Y, J Gunst S . Silencing of p21-activated kinase attenuates vimentin phosphorylation on Ser-56 and reorientation of the vimentin network during stimulation of smooth muscle cells by 5-hydroxytryptamine. Biochem J. 2005; 388(Pt 3):773-83. PMC: 1183456. DOI: 10.1042/BJ20050065. View

Shasby D, Ries D, Shasby S, Winter M . Histamine stimulates phosphorylation of adherens junction proteins and alters their link to vimentin. Am J Physiol Lung Cell Mol Physiol. 2002; 282(6):L1330-8. DOI: 10.1152/ajplung.00329.2001. View

Mercado C, Ziu E, Kilic F . Communication between 5-HT and small GTPases. Curr Opin Pharmacol. 2011; 11(1):23-8. PMC: 3073727. DOI: 10.1016/j.coph.2011.01.006. View

Tanaka T, Mori M, Sekino M, Higashijima U, Takaki M, Yamashita Y . Impact of plasma 5-hydroxyindoleacetic acid, a serotonin metabolite, on clinical outcome in septic shock, and its effect on vascular permeability. Sci Rep. 2021; 11(1):14146. PMC: 8266895. DOI: 10.1038/s41598-021-93649-z. View

10.

Wenzel R, Edmond M . Septic shock--evaluating another failed treatment. N Engl J Med. 2012; 366(22):2122-4. DOI: 10.1056/NEJMe1203412. View

11.

Mendez M, Kojima S, Goldman R . Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010; 24(6):1838-51. PMC: 2874471. DOI: 10.1096/fj.09-151639. View

12.

Rowley D, BENDITT E . 5-Hydroxytryptamine and histamine as mediators of the vascular injury produced by agents which damage mast cells in rats. J Exp Med. 1956; 103(4):399-412. PMC: 2180352. DOI: 10.1084/jem.103.4.399. View

13.

Duerschmied D, Suidan G, Demers M, Herr N, Carbo C, Brill A . Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood. 2012; 121(6):1008-15. PMC: 3567335. DOI: 10.1182/blood-2012-06-437392. View

14.

Galecki P, Mossakowska-Wojcik J, Talarowska M . The anti-inflammatory mechanism of antidepressants - SSRIs, SNRIs. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 80(Pt C):291-294. DOI: 10.1016/j.pnpbp.2017.03.016. View

15.

McNicol A, Israels S . Platelets and anti-platelet therapy. J Pharmacol Sci. 2004; 93(4):381-96. DOI: 10.1254/jphs.93.381. View

16.

Kilic F, Rudnick G . Oligomerization of serotonin transporter and its functional consequences. Proc Natl Acad Sci U S A. 2000; 97(7):3106-11. PMC: 16200. DOI: 10.1073/pnas.97.7.3106. View

17.

Schortgen F, Asfar P . Update in sepsis and acute kidney injury 2014. Am J Respir Crit Care Med. 2015; 191(11):1226-31. DOI: 10.1164/rccm.201502-0307UP. View

18.

Dejana E . Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. 2004; 5(4):261-70. DOI: 10.1038/nrm1357. View

19.

Wang Z, Holthoff J, Seely K, Pathak E, Spencer 3rd H, Gokden N . Development of oxidative stress in the peritubular capillary microenvironment mediates sepsis-induced renal microcirculatory failure and acute kidney injury. Am J Pathol. 2011; 180(2):505-16. PMC: 3349842. DOI: 10.1016/j.ajpath.2011.10.011. View

20.

Walker F . A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?. Neuropharmacology. 2012; 67:304-17. DOI: 10.1016/j.neuropharm.2012.10.002. View